CALR and plasma cell myeloma: In addition, the cytotoxicity assay confirmed that our DNA vaccine can induce a specific CTL response targeting myeloma cells, and the use of CRT as an immune adjuvant can further amplify the anti-myeloma immune response induced by the CS1-DNA vaccine (Figure 6).